Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin

Authors

Sunil Parikh, University of California - San Francisco
Jun Liu, Washington University School of Medicine in St. Louis
Puran Sijwali, University of California - San Francisco
Jiri Gut, University of California - San Francisco
Daniel E. Goldberg, Washington University School of Medicine in St. LouisFollow
Philip J. Rosenthal, University of California - San Francisco

Journal

Antimicrobial Agents and Chemotherapy

Publication Date

2006

Volume

50

Issue

6

Inclusive Pages

2207

Document Type

Open Access Publication

DOI

10.1128/AAC.00022-06

Rights and Permissions

Parikh, S., Liu, J., Sijwali, P., Gut, J., Goldberg, D. E., & Rosenthal, P. J. (2006). Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin. Antimicrobial Agents and Chemotherapy, 50(6), 2207-2209. DOI:10.1128/AAC.00022-06

Recommended Citation

Parikh, Sunil; Liu, Jun; Sijwali, Puran; Gut, Jiri; Goldberg, Daniel E.; and Rosenthal, Philip J., "Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin." Antimicrobial Agents and Chemotherapy. 50, 6. 2207. (2006).
https://digitalcommons.wustl.edu/open_access_pubs/2363